Objective-Deep vein thrombosis (VT) can result in vein wall injury, which clinically manifests as post-thrombotic syndrome. Postinjury fibrosis may be modulated in part through cellular cysteine-cysteine receptor 7 (CCR7)-mediated events. We tested the hypothesis that late vein wall fibrotic remodeling is dependent on CCR7. Approach and Results-CCR7 −/− and C57BL/6 wild-type mice had inferior vena cava VT induced by nonstasis or stasis mechanisms. In both models, VT size was largest at day 1 and trended down by day 21, and CCR7 + cells peaked at day 8 in wild-type mice. No significant differences in VT resolution were found in CCR7 −/− as compared with wild type in either model. In the nonstasis VT model, vein wall changes consistent with fibrotic injury were evidenced by significant increases in collagen I, III, matrix metalloproteinase 2, and transforming growth factor-β gene expression, increases in αsmooth muscle actin and fibroblast specific protein-1 antigen, and total collagen at 8 days. Correspondingly, SM22α and fibroblast specific protein-1, but not DDR2 + cells, were increased at 8 days. Early wild-type thrombus exposure inhibited profibrotic gene expression in CCR7 −/− in ex vivo vein wall culture. Bone marrow chimera experiments further showed that circulating CCR7 + leukocytes partially rescued midterm profibrotic changes in CCR7 −/− mice. In human histological sections of chronic thrombosed femoral veins, CCR7 + cells were present in the fibrotic areas. Conclusions-Post-thrombotic vein wall remodeling is impaired in CCR7 −/− mice, with a profibrotic phenotype, is dependent on the thrombotic mechanism, and is mediated by circulating CCR7 + cells. Unlike other postinjury fibrotic responses, CCR7 + signaling may be important for positive vein wall remodeling after VT. (Arterioscler Thromb Vasc Biol. 2014;34:377-385.) The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
D eep vein thrombosis (DVT) remains a significant problem in the United States despite widespread prophylaxis, with ≈250 000 patients affected annually. 1 Long-term sequelae exist in the form of post-thrombotic syndrome (PTS), occurring in ≤25% of patients with DVT. 2, 3 PTS is characterized by a fibrotic vein wall injury which clinically manifests as leg swelling, pain, and ulceration because of venous insufficiency. 3 Current therapy for PTS is mainly palliative with graded compression stockings, elevation, and wound care. Anticoagulants, such as low-molecular-weight heparin, are effective when used for DVT prophylaxis and treatment but are associated with bleeding risks, and no evidence exists that these agents significantly decrease PTS. 2 Venous thrombosis pathophysiology is now better understood from experimental studies in the mouse, rat, and primate. Leukocytes, chemokines, and proinflammatory cytokines are all involved in the process of thrombus resolution and vein wall healing. 4, 5 This process resembles wound healing in the distinct phases of neutrophil (PMN) and monocyte influx, with thrombus angiogenesis, followed by fibrosis. Leukocyte influx into the thrombus and juxtaposed vein wall is important for thrombus resolution, [6] [7] [8] [9] but the mechanisms of vein wall fibrosis have only been partially characterized. 10 One recently described mechanism of postinjury vascular fibrosis is endothelial to mesenchymal transition (EndMT). 11, 12 Phenotypically, several markers are suggestive of EndMT, including gain of mesenchymal markers, such as α-smooth muscle actin, SM22α, and fibroblast specific protein-1 (FSP-1), and loss of endothelial markers, such as vascular endothelial cadherin and CD31. This is often triggered by exposure to a defined injury, as observed in models of cardiac fibrosis, pulmonary hypertension, and diabetic nephropathy. [12] [13] [14] [15] Chemokines are ubiquitous small signaling peptides that are essential for chemotaxis and activation of leukocytes and may contribute to organ fibrosis. 16 Leukocytes that express cysteine-cysteine receptor 7 (CCR7) have been shown to play a role in experimental fibrosis models. For example, direct CCR7 antibody inhibition reduces fibrosis in lung and kidney injury models. 17, 18 A primary ligand for CCR7 is CCL21 (secondary lymphoid chemokine [SLC]), which is primarily produced by monocytes and resident tissue cells, such as fibroblasts, and is stimulated by proinflammatory chemokines. 19 SLC has been shown to play a pivotal role in CCR7 + cell migration in wound healing, arterial plaque progression, and experimental fibrotic lung injury models. 17, 20, 21 Another chemokine ligand for CCR7 is CCL19 (EBI1 ligand chemokine [ELC]) but has primarily been associated with lymph node and dendritic cell development 22 and not with postinjury fibrosis.
The purpose of this study was to evaluate the role of CCR7 signaling on vein wall fibrotic remodeling over time using 2 models of VT. Contrary to our primary hypothesis, the lack of CCR7 signaling worsened the post-thrombotic vein wall fibrotic changes but was partially rescued with either wild-type (WT) ex vivo thrombus exposure or in vivo reconstitution of the CCR7 −/− mice with WT bone marrow.
Materials and Methods
Materials and methods are available in the online-only Supplement.
Results

Human Chronic Post-Thrombotic Vein Wall Tissue Show CCR7 + Leukocyte Staining and Decreased Circulating Leukocyte CCR7 Gene Expression in Acute DVT
We first determined by real-time polymerase chain reaction leukocyte gene expression of CCR7 from human samples, from a prior published study on vein wall remodeling. 23 All patients had their DVT in ilio-femoral-popliteal location and were treated with standard anticoagulation. We found that, as compared with healthy controls, a significant decrease in CCR7 expression was observed ( Figure 1 ). Next, CCR7 + staining in human post chronic DVT surgical histological specimens (n=3), ranging from 2 to 7 years postacute DVT. Interestingly, the CCR7 + staining was generally in the middle of the fibrotic vein wall and not surrounding neovascularized areas. The histological morphology was consistent with mononuclear cells. Together, these descriptive data suggest that the CCR7 signaling axis is involved with acute circulating leukocytes and chronic DVT tissue in humans.
Venous Thrombosis Resolution Is Not Affected in CCR7 −/− Mice
Thrombus size decreases over time in the nonstasis model, similar to the stasis model and consistent re-establishment of perivenous blood flow. 24 Comparison of WT and CCR7 −/− thrombus size at days 1, 8, and 21 showed no significant difference by standard weight to length measurement ( Figure I in the online-only Data Supplement). Comparison of thrombus fibrinogen and plasmin levels also showed no significant differences at day 1 or day 8 (not shown). To assess thrombus proinflammatory cytokine markers, 4 interleukin-1α, interleukin-6, tumor necrosis factor-α, and monocyte chemoattractant protein-1 were measured. No differences between WT and CCR7 −/− mice were found at either day 1 or day 8 in any other cytokine levels over time (not shown). Last, no difference in day 1 thrombus PMNs was found between WT and CCR7 −/− (41±7 versus 42±8 cells/5 high-power fields; n=6; P=0.9). These data suggest that thrombogenesis and thrombus resolution were not directly affected by lack of CCR7 signaling.
Vein Wall SLC and ELC Kinetics Are Altered in CCR7 −/− Mice
Comparison of SLC and ELC vein wall levels is shown (Figure 2A and 2B). SLC protein was elevated 1.5-fold in the CCR7 −/− vein wall at day 1 (n=6; P=0.02), whereas levels were similar at day 8. By day 21, SLC was elevated 1.8-fold in the WT mice as compared with CCR7 −/− mice. Comparatively, a similar trend was noted for the ELC kinetics. Here, ELC wall levels were 1.8-fold greater at day 1 and not different at day 8. By day 21, ELC was 1.9-fold greater in WT as compared with CCR7 −/− . The absolute vein wall levels of SLC were greater than ELC at any given time point.
Vein wall CCR7 + cells were quantified over time in WT mice ( Figure 2C and 2D). At day 1, few CCR7 + cells were present in the vein wall or thrombus. However, an 8-fold increase occurred between day 1 and day 8, with this persisting through day 21. Morphologically, CCR7 + cells were mononuclear and were present in the vein wall and thrombusvein wall interface at day 8 and primarily in the media of the vein wall at day 21.
Midterm Vein Wall Fibrosis Is Increased in CCR7 −/− Mice With Features of EndMT
Fibrotic mediators that are known to be involved with CCR7mediated processes were assessed in the vein wall and include transforming growth factor-β (TGF-β), collagen, and matrix metalloproteinase (MMP) gene expression over time. 20, 25 First, vein wall TGF-β gene expression was elevated ≈4-fold in CCR7 −/− as compared with WT at 8 days, but no significant difference was found at 21 days ( Figure 3A ). Vein wall collagen-α2 (I) gene expression was elevated in CCR7 −/− ≈8-fold at day 8 and 5-fold at day 21 as compared with WT ( Figure 3B ). A similar relationship at 8 days was observed with collagen-α1 (III) gene expression, with a 20-fold elevation in CCR7 −/− as compared with WT and 9-fold at day 21 Figure 3C ). Correspondingly, the collagen content of the vein wall was elevated 2-fold at day 8 in CCR7 −/− as compared with WT (117±15 versus 68±13 μg/mg protein; n=5-6; P=0.048).
Nonstandard Abbreviations and Acronyms
One mechanism of vessel wall response to injury is EndMT, characterized by an increase in collagenolytic activity, medial cell mesenchymal markers, and decrease in endothelial markers. 12, 13 To determine whether phenotypic markers of this process were present, we assessed several markers of EndMT in post-thrombotic day 8 vein walls. MMP2 gene expression was elevated 20-fold at day 8 in CCR7 −/− as compared with WT but was not significantly different at day 21 ( Figure 3D ). Consistently, active MMP2 zymographic activity was increased 2-fold at day 21 in the CCR7 −/− mice as compared with WT mice ( Figure 3E ). Because tissue inhibitor of metalloproteinases balance MMP activity, we assessed for tissue inhibitor of metalloproteinase-1 antigen levels. We found that tissue inhibitor of metalloproteinase-1 was significantly elevated at days 8 and 21 in CCR7 −/− vein walls as compared with WT ( Figure 3F ). Vein wall MMP9 gene expression and vein wall MMP9 zymographic activity were not significantly different at day 8 or day 21 in CCR7 −/− as compared with WT (not shown).
Histological evaluation showed that 2-fold more SM22α + cells were present in day 8 CCR7 −/− vein walls as compared with WT, reflective of vascular smooth muscle cells ( Figure 4C ). The SM22α + cells were present only in the vein wall and not in the thrombus-vein wall interface. Consistently, 3-fold more FSP-1 + cells (myofibroblast marker) 26 in the vein wall and perithrombus region were present in CCR7 −/− as compared with WT ( Figure 4D ), but no difference was found in DDR2 + cells (fibroblast marker 27 ; 86±8 versus 75±6 cells/5 high-power fields; n=5-7; P=0. 35 ). We also found increased α-smooth muscle actin and FSP-1 antigen by Western immunoblotting as compared with WT ( Figure 4A and 4B). Last, confocal microscopy for CD31/FSP-1 staining was done showing CCR7 −/− sections but not WT controls (n=3) with positive dual staining cells at the vein wall-thrombus interface ( Figure 4E and 4F).
Evaluating the late vein wall response at day 21, we found no significant differences in fibrosis or any endothelial or fibrotic protein markers. For example, FSP-1 + cells were not significantly different between the CCR7 −/− and WT at day 21 (2.8±1 versus 2.7±; n= 5, P=0.98) and were reduced 5-fold in magnitude from day 8 in both CCR7 −/− and WT. Because the vein and thrombus are densely adherent after day 8, we assessed collagen content by histological picrosirius red analysis. A trend was noted, but this did not reach statistical significance ( Figure II in the online-only Data Supplement).
Early Thrombus-Exposed Ex Vivo Vein Wall Profibrotic Gene Expression Response Is Dependent on CCR7
Given that CCR7 signaling is associated with a profibrotic phenotype in vivo, we used a novel ex vivo vein wall culture 28 to isolate the vein wall and the thrombus effect. We exposed naive vein wall (w) of either WT or CCR7 −/− , in a cross-factorial fashion, to 2 days WT or CCR7 −/− in vivo derived thrombus (t) by the nonstasis mechanism. This approach eliminates the circulating leukocyte's effect outside of what may be trapped in the thrombus at the time of harvest. Thus, the nonexposed vein wall is exposed to only the thrombus milieu.
We examined the vein wall gene expression of several profibrotic factors that were elevated in vivo in the CCR7 −/− mice. Gene expression of all factors assayed in the control, nonthrombus-exposed WT and CCR7 −/− vein walls showed no significant differences (data not shown), suggesting no baseline genotype differences in vein wall response to organ culture. These were combined for further analysis.
The WT t to WT w and CCR7 −/− t to WT w was associated with no induction of collagen I, III, or MMP2 gene expression as compared with nonexposed control ( Figure 5A-5D ). However, CCR7 −/− t to CCR7 −/− w was associated with significant elevation in profibrotic gene expression, yet no difference was found in TGF-β expression. Interestingly, the WT t to Figure 1 . A, Leukocyte fraction of whole blood was processed for gene expression of cysteine-cysteine receptor 7 (CCR7). As compared with control (ctl) non-deep vein thrombosis (DVT) patients (n=10), a significant decrease in leukocyte CCR7 expression was found at enrollment (n=12) and at 6 months (n=10). B to D, Human histological section of fibrosed femoral vein after DVT (>12 months) showing numerous CCR7 + cells within section. Arrows denote positive cells. February 2014 CCR7 −/− w resulted in a significant decrease in profibrotic gene elevation, with no effect on TGF-β expression. Conversely, the CCR7 −/− t did not induce profibrotic gene expression in WT walls. Examination of direct vein wall (WT or CCR7 −/− ) exposure to SLC, ELC, or the combination thereof did not induce profibrotic gene expression as compared with control (data not shown). Evaluation of the WT thrombus factors possibly directing this response included TGF-β, platelet-derived growth factor, RANTES, and platelet factor 4. As compared with WT, platelet-derived growth factor was less in the CCR7 −/− thrombi (130±36 versus 273±50 pg/mg protein; n=5; P=0.04), whereas the other profibrotic mediators were not different. Consistently, the CCR7 −/− t to WT w was associated with lower collagen I and III expression as compared with WT t to WT w (0.5<P<0.10).
Circulating CCR7 + Cells Drive Fibrotic Histological Changes
To further isolate the effect of CCR7 + cell function in vivo, we used bone marrow chimeras with WT or CCR7 −/− bone marrow rescue, with tissue harvest at 8 days in the nonstasis VT model. We assessed vein wall histology for mesenchymal markers that were altered with the CCR7 −/− response ( Figure 3C and 3D). We found a similar and significant elevation of SM22α + and FSP-1 + cells in the CCR7 −/− bone marrow to CCR7 −/− recipients as compared with WT to WT bone marrow reconstitution ( Figure 6 ). The WT bone marrow to CCR7 −/− mice significantly reduced the SM22α + and FSP-1 + cellular marker elevation, but the reconstitution did not bring cell markers fully back to WT levels. Interestingly, CCR7 −/− bone marrow to WT recipients was associated with significant elevation of SM22α + and FSP-1 + cells in the vein wall as compared with WT to WT controls (P<0.001). These data suggest that bone marrow-derived CCR7 + cells in vivo direct the fibrotic marker expression at 8 days post thrombosis.
CCR7 Deletion Minimally Affects Vein Wall Remodeling in a Stasis Model of VT
Given that CCR7 signaling directly affects post-thrombotic vein wall remodeling in the nonstasis model, we performed a similar analysis on our standard stasis inferior vena cava ligation model. 29 The thrombus sizes were bigger at any given time point in the stasis as compared with nonstasis models ( Figure IIIa in the online-only Data Supplement). As in nonstasis model, there was no significant difference in thrombus size between CCR7 −/− and WT mice at any time point.
The vein wall SLC and ELC kinetics were different than the nonstasis model, with no significant early elevation of either chemokine ( Figure IIIb and IIIc in the online-only Data Supplement). Only ELC at day 21 was less in CCR7 −/− as compared with WT. The CCR7 counts in WT were similar at day 8 to the nonstasis model (41±5 versus 46±11 cells/5 highpower fields; n=5; P=not significant). However, at day 21, the CCR7 + cells were significantly less in the WT stasis as compared with nonstasis (11±6 versus 37±8 cells/5 high-power fields; n=4; P<0.05).
Unlike the nonstasis model and CCR7 signaling, we found no significant changes in gene expression of collagen I or collagen III in the CCR7 −/− mice as compared with WT mice at day 8. Consistently, no difference in vein wall collagen content was found between WT and CCR7 −/− at day 8 ( Figure  IIId -IIIf in the online-only Data Supplement). Picrosirius red comparison of vein wall collagen content at day 21 also showed significant differences (data not shown).
Discussion
PTS is not uncommon after DVT, and no direct therapy exists to prevent or treat it. 2 The pathological process is related to venous hypertension with resulting fibrosis with loss of venous compliance. Herein, we focused on the mid and later time points of vein wall response, consistent with early PTS in humans. Multiple factors play a role in postinjury vascular responses, and CCR7 + leukocytes are present in arterial, pulmonary, and renal models of fibrotic injury. 17, 18, 21 Based on these injury models, our initial hypothesis was that CCR7 + cells and signaling pathway would promote vein wall fibrosis; that is, CCR7 −/− mice would be protected from experimental postthrombotic vein wall fibrosis. To our surprise, deletion of CCR7 was associated with increased vein wall midterm fibrosis and mesenchymal cell changes. The primary findings of this study are as follows: (1) circulating leukocyte CCR7 gene expression is decreased in acute DVT, and CCR7 + cells are present in human chronic post-thrombotic vein walls; (2) CCR7 signaling does not affect VT resolution; (3) midterm vein wall fibrosis is increased in CCR7 −/− mice; (4) thrombus character ex vivo partially affects the vein wall fibrotic gene expression; (5) circulating CCR7 + cells drive histological vein wall fibrotic changes; and (6) the CCR7 signaling effects are model dependent.
The venous thrombus models used provide tissue that represents a balance of thrombogenesis and thrombolysis at the given time point of harvest. 29 These models reflect what occurs in humans with segmental areas of perithrombus blood flow and total stasis. 30, 31 Deletion of CCR7 signaling did not alter the VT resolution, as measured by VT size. Consistently, levels of thrombus plasmin, fibrinogen, or proinflammatory cytokines were not different between CCR7 −/− and WT mice. In our models, thrombus size is affected by chemokine-directed PMN and monocyte activities. 6, 7, 32 No difference in early PMN thrombus influx was found at day 1 between CCR7 −/− and WT, again consistent with a lack of effect on thrombus resolution. Macroscopically, the CCR7 −/− thrombus consistency did not seem more friable or loose, and no documented pulmonary emboli or unusual deaths were noted. Similarly, no difference between CCR7 −/− and WT in VT resolution was found in the stasis model of VT. Thus, although CCR7 + cells are present in the thrombus periphery, their direct role seems minimal in the thrombogenic and resolution process.
The human tissue data, although descriptive, show that CCR7 gene expression is reduced in those patients with acute DVT and that in chronic resolving DVT-associated vein scar, CCR7 + mononuclear morphology cells are present. Our data do not allow us to say whether the reduced circulating leukocyte CCR7 gene expression was present in those patients before the DVT or whether this is related to the acute and chronic DVT (eg, predictor versus consequence). We further acknowledge that we do not have correlative CCL19 and CCL21 circulating antigen data in humans as a limitation. Although we do not have tissue from patients with DVT who fully resolved their DVT (and hence no specimen), the fact that CCR7 + cells are present in human vein wall remodeling provides crucial translational support for the mouse experimental data herein. Others have found the cellular evidence of SLC-CCR7 axis in human atherosclerotic plaques. 21 Together, these findings suggest that SLC-CCR7 axis is involved with both arterial and venous vessel response to injury.
Although cell lineage tracing experiments were not performed that would prove EndMT is taking place, some of the observed phenotypic changes in the vein wall were consistent with EndMT at the midterm time point. For example, TGF-β may stimulate native medial vascular cells to increase collagen I and α-smooth muscle actin expression, 25 as well as directly induce EndMT. 14, 33 Consistent with this notion was increased vein wall TGF-β and collagen I and III gene expression observed in CCR7 −/− mice, and was correlated with net collagen gain in the vein wall at 8 days. Increased mesenchymal markers were also found in post-thrombotic vein walls of CCR7 −/− mice, as reflected by an increase in α-smooth muscle actin and FSP-1 protein, an increase in FSP-1 + and SM22α + cells (mesenchymal markers), and colocalization of CD31/ FSP-1-stained cells at the vein wall-thrombus interface. Elevated MMP2 gene expression at day 8 and activity at day 21 is also consistent with EndMT 12, 34 and was associated with elevated tissue inhibitor of metalloproteinase-1 expression. Interestingly, vascular fibroblast cell number (DDR2 + ) was not affected by CCR7 deletion, again suggesting that myofibroblast activation 26 is primary to the CCR7-mediated fibrotic response observed. However, a decrease in endothelial markers was not observed at any time point. Last, only a trend of increased vein wall collagen at day 21 was observed. This may be a limitation of our analytic method 23, 35 with the adherent thrombus at that time point as compared with earlier time points or that other mechanisms promote collagenolysis at the later time point. Consistently, fewer yet similar numbers of FSP-1 + cells in WT and CCR7 −/− vein walls were found at day 21, and these cells are known to drive fibrosis. 34 Venous thrombosis in both models induced vein wall production of both SLC and ELC, was affected by CCR7 −/− genotype (eg, increased early SLC and ELC in CCR7 −/− ), and may represent a mechanism to mitigate excessive fibrosis by attracting CCR7 + circulating cells. The peak of SLC/ELC and CCR7 + cells corresponded because they were most numerous in WT vein wall at 8 days and thereafter, consistent with the timing of vein wall fibrotic change in rodents. 10 Consistently, in a dermal injury model, exogenous SLC was associated with accelerated wound healing and less inflammation associated with CCR7 + cell influx. 36 Moreover, in experimental arterial vascular injury, arterial wall SLC/ELC was upregulated, and exogenous statin administration was associated with increased circulating CCR7 + cells and a healing response. 21 Our data and others suggest a provascular healing effect of CCR7 signaling and are also underscored by the presence of CCR7 + cells in the human sections. 37 We did not directly assess whether the CCR7 + cells were consistent with circulating fibrocytes (CCR7 + /Col-I + /CD45 + ), but is not likely, as these cells contribute to fibrosis in epithelia-lined structures, such as cutaneous would healing 20 and pulmonary fibrosis, 17 but little data exist these play a role in postinjury vascular fibrosis.
Modarai et al 8 used a green fluorescent protein-bone marrow reconstitution strategy to evaluate the circulating leukocytes' role in experimental VT, showing the majority of bone marrow-derived leukocytes were in the thrombus periphery and less so in the vein wall after thrombosis. This is consistent with the location of CCR7 + cells in both the wall and thrombus periphery in the current study and suggests a type of mesenchymal stem cell. These cells can differentiate in areas of the vasculature which have been damaged to promote restoration of function. 38 Our data suggest that these circulating CCR7 + leukocytes act as a modulator of post-VT fibrosis, as shown by partial but significant reversal to the WT vein wall SM22α and FSP-1 vein wall phenotype. Conversely, reconstitution of WT bone marrow with CCR7 −/− bone marrow significantly affected the WT vein wall response, with marked induction of FSP-1 + and SM22α markers. The ex vivo vein wall culture also showed that the WT thrombus could blunt the profibrotic gene expression elevation in the CCR7 −/− vein walls. In contrast to the in vivo bone marrow experiments, the CCR7 −/− thrombus itself did not induce profibrotic gene expression in WT vein walls, yet did affect CCR7 −/− wall profibrotic gene expression. Thus, it seems the CCR7 −/− vein wall may be primed for profibrotic expression, and depending on the circulating CCR7 leukocyte status when the thrombus is formed, either upregulation or minimal change occurs. The fact that thrombus profibrotic inflammatory mediators (except platelet-derived growth factor) were not different between groups suggests the influxing CCR7 + cells more likely drive the vein wall responses than the thrombus milieu. The exact mechanism of how CCR7 + leukocytes prevent fibrosis is not clear. The CCR7 + cells may inhibit intrinsic conversion of medial vein wall cells to FSP-1 + and SM22α + , directly affect cellular proliferation and mesenchymal cell emigration, or affect microRNA signaling. 14 Given what occurs in humans with stasis and nonstasis segments of vein after DVT, 2 we also examined the role of CCR7 signaling in a full stasis thrombosis model. Our data suggest that the stasis mechanism of thrombosis may dominate the effects conferred by CCR7 + cells because there were few major differences in the fibrotic vein wall phenotype after stasis VT at day 8 or day 21 between CCR7 −/− and WT. Thus, perivenous blood flow may be critical for CCR7 signaling activity (and likely flux of CCR7 + cells) and positive vein wall remodeling. It may also be that a static thrombus drives other mechanisms involved with vein wall responses, such as the plasmin and MMP system. 10, 39 Further work will characterize the role of CCR7 agonism to promote nonfibrotic vein wall repair after DVT, but currently no clinically available pharmacological agents exist. Moreover, whether this agent would distribute in the resolving VT is not clear, but is worthy of exploration because no direct therapy exists to treat PTS in humans.
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None. Figure 6 . Bone marrow chimera experiments, all harvested at day 8 post thrombosis. A, By immunohistology, SM22α + cell staining was decreased in wild type (WT) to CCR7 −/− as compared with CCR7 −/− to CCR7 −/− , whereas CCR7 −/− to WT increased SM22α + staining cells. B, Vein wall FSP-1 + cell staining was decreased in WT to CCR7 −/− as compared with CCR7 −/− to CCR7 −/− , whereas CCR7 −/− to WT increased FSP-1 + staining. Immunohistologic sections show the WT to CCR7 −/− and CCR7 −/− to WT recipients at ×400. Arrows denote positive cells. T indicates thrombus; and W, wall. *P<0.05 comparing CCR7 −/− to WT and WT to WT. Data represent mean±SEM of 5 to 6 mice in each group. CCR7 indicates cysteine-cysteine receptor 7; and HPFs, high-power fields.
